Table 4.
Corticosteroids | 23 patients (50.0%) |
Rituximab | 16 patients (34.8%) |
Mycophenolate mofetil | 5 patients (10.9%) |
Azathioprine | 4 patients (8.7%) |
Mercaptopurine | 2 patients (4.3%) |
Hydroxychloroquine | 2 patients (4.3%) |
Abatacept | 1 patient (2.2%) |
Sirolimus | 1 patient (2.2%) |
Cyclosporine | 1 patient (2.2%) |